Zheleza sakharat: rol' v lechenii anemii pri khronicheskoy bolezni pochek
- Autores: Fomin V.V1
-
Afiliações:
- Edição: Nº 4 (2012)
- Páginas: 59-62
- Seção: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/261672
- ID: 261672
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Обсуждается роль железа сахарата в лечении анемии при хронической болезни почек.
Palavras-chave
Texto integral
Bibliografia
- Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356: 147—152.
- Silverberg D.S., Wexler D., Blum M. et al. The cardio-renal syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin. Nephrol. 2003; 60: S93-S102.
- Levin A., Thompson C.R., Ethier J. et al. Left ventricular mass index increase in early renal disease: impact of decline of hemoglobin. Am. J. Kidney Dis. 1999;34:768- 776.
- Macdougall I.C., Chandler G., Elston O. et al. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. Am. J. Kidney Dis. 1999;34 (Suppl. 2): S40-S46.
- Schiesser D., Binet I., Tsinalis D. et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol. Dial. Transplant. 2006; 21(10): 2841-2845.
- Macdougall I.C. The role of ACE inhibitors and angiotensin I Ireceptor blockers in the response to epoetin. Nephrol. Dial. Transplant. 1999;14: 1836-1841.
- London G.M, Fabiani F., Marchais S.J. et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987; 31: 973-980.
- Greaves S.C., Gamble G.D., Collins J.F. et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am. J. Kidney Dis. 1994; 24: 768-776.
- Madore F., Lowrie E.G., Brugnara C. et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J. Am. Soc. Nephrol. 1997; 8:1921-1929.
- Козловская Л.В., Милованов Ю.С., Фомин В.В. и др. Анемическая кардиомиопатия. Анемия. 2004;1:29-35.
- Deicher R., Horl W.H. Anaemia as a risk for the progression of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2003;12:139-143.
- Mohanram A., Zhang Z, Shahinfar S. et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004; 66:1131-1138.
- Silverberg D.S., Iaina A., Peer G. et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am. J Kidney Dis. 1996;27(2):234-238.
- Silverberg D.S., Blum M., Peer G. et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron. 1996;72(3):413-417.
- Macdougall I.C., Chandler G., Elston O. et al. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. Am. J. Kidney Dis. 1999;34 (Suppl. 2):S40-S46.
- Van Vyck D.B. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy. Nephrol. Dial. Transplant. 2000;15(Suppl. 3):36-39.
- Sander-Plassmann G., Horl W. Importance of iron supply for erythropoietin therapy. Nephrol. Dial. Transplant. 1995;10:979-987.
- Charytan C., Levin N., Al-Saloum M. et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial. Am. J. Kidney Dis. 2001;37:300-307.
- Singh H., Reed J., Noble S. et al. United States Iron Sucrose (Venofer) Clinical Trials Group. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin. J. Am. Soc. Nephrol. 2006;1(3):475-482.
- Li H., Wang S.X. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit. Dial. Int. 2008;28(2):149-154.
- Malovrh M., Hojs N., Premru V. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents. Artif. Organs. 2011;35(1):63-68.
- Solak Y., Atalay H., Guney I. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients. Ren. Fail. 2011;33(3):307-311.
- Pollak V.E., Lorch J.A., Shukla R. et al. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol. 2009;10:6.
- Comin-Colet J., Ruiz S., Cladellas M. et al. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J. Card Fail. 2009;15(9):727-735.
- Шило В.Ю., Денисов А.Ю. Сахарат железа в лечении анемии у больных на программном гемодиализе. Украинский журнал нефрологии и диализа. 2010;3:37-45.
- Бирюкова Л.С., Федорова Н.Д., Кирхман В.В. и др. Использование Венофера для лечения анемии при хронической почечной недостаточности. Нефрология и диализ. 2003;5(1):55-58.
- Lunde N., Pennell P., Charytan C. et al. Safety of iron sucrose in the general hemodialysis population. J. Am. Soc. Nephrol. 2001;12:359A-360A.
- Charytan C., Levin N., Al-Saloum M. et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am. J. Kidney Dis. 2001;37(2):300-307.
- Van Wyck D.B., Cavallo G., Spinowitz B.S. et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am. J Kidney Dis. 2000;36:88-97.
- Rottembourg J., Kadri A., Leonard E. et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol. Dial. Transplant. 2011;26(10):3262-3267.
Arquivos suplementares
